About Lipocine Inc.
https://www.lipocine.comLipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy.
CEO
Mahesh V. Patel
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-05-12 | Reverse | 1:17 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
VHCP MANAGEMENT, LLC
Shares:849.92K
Value:$9.35M
BLACKROCK FUND ADVISORS
Shares:538.1K
Value:$5.92M
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A.
Shares:365.85K
Value:$4.02M
Summary
Showing Top 3 of 35
About Lipocine Inc.
https://www.lipocine.comLipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $114.57K ▼ | $3.48M ▲ | $-3.19M ▼ | -2.78K% ▼ | $-0.59 ▼ | $-3.34M ▼ |
| Q2-2025 | $622.85K ▲ | $890.43K ▼ | $-2.21M ▼ | -354.13% ▲ | $-0.41 ▼ | $-2.39M ▼ |
| Q1-2025 | $93.86K ▼ | $2.18M ▲ | $-1.86M ▼ | -1.99K% ▼ | $-0.35 ▼ | $-2.07M ▼ |
| Q4-2024 | $3.49M ▲ | $1.95M ▼ | $1.78M ▲ | 51.04% ▲ | $0.33 ▲ | $1.56M ▲ |
| Q3-2024 | $0 | $2.63M | $-2.22M | 0% | $-0.41 | $-2.62M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $15.13M ▼ | $16.07M ▼ | $1.93M ▲ | $14.14M ▼ |
| Q2-2025 | $17.94M ▼ | $18.58M ▼ | $1.45M ▲ | $17.13M ▼ |
| Q1-2025 | $19.72M ▼ | $20.5M ▼ | $1.3M ▼ | $19.2M ▼ |
| Q4-2024 | $21.63M ▲ | $22.51M ▲ | $1.51M ▼ | $21M ▲ |
| Q3-2024 | $19.82M | $20.7M | $1.58M | $19.12M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-3.19M ▼ | $-2.99M ▼ | $701.45K ▼ | $141.33K ▲ | $-2.14M ▼ | $-2.99M ▼ |
| Q2-2025 | $-2.21M ▼ | $-1.89M ▲ | $4.5M ▲ | $75.62K ▲ | $2.69M ▲ | $-1.89M ▲ |
| Q1-2025 | $-1.86M ▼ | $-1.97M ▼ | $-882.07K ▼ | $0 | $-2.85M ▼ | $-1.97M ▼ |
| Q4-2024 | $1.78M ▲ | $1.7M ▲ | $761.06K ▼ | $0 | $2.46M ▲ | $1.69M ▲ |
| Q3-2024 | $-2.22M | $-2.83M | $1.02M | $0 | $-1.81M | $-2.91M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|
 License | $0 ▲ | $0 ▲ | $0 ▲ |
 Reportable Segment | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Mahesh V. Patel
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-05-12 | Reverse | 1:17 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
VHCP MANAGEMENT, LLC
Shares:849.92K
Value:$9.35M
BLACKROCK FUND ADVISORS
Shares:538.1K
Value:$5.92M
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A.
Shares:365.85K
Value:$4.02M
Summary
Showing Top 3 of 35